[(3R)-1-[(2R,3R,4R,5S,6R)-2-[[(2R,3S,4R,5R,6R)-3-hydroxy-4-[(3R)-3-hydroxydecoxy]-5-(3-oxotetradecanoylamino)-6-phosphonooxyoxan-2-yl]methoxy]-6-(methoxymethyl)-3-(3-oxotetradecanoylamino)-5-phosphonooxyoxan-4-yl]oxydecan-3-yl] (Z)-dodec-5-enoate (BioDeep_00000838691)
代谢物信息卡片
[(3R)-1-[(2R,3R,4R,5S,6R)-2-[[(2R,3S,4R,5R,6R)-3-hydroxy-4-[(3R)-3-hydroxydecoxy]-5-(3-oxotetradecanoylamino)-6-phosphonooxyoxan-2-yl]methoxy]-6-(methoxymethyl)-3-(3-oxotetradecanoylamino)-5-phosphonooxyoxan-4-yl]oxydecan-3-yl] (Z)-dodec-5-enoate
化学式: C73H136N2O22P2 (1454.9059496)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCCCCCCCCC(=O)CC(=O)NC1C(C(C(OC1OP(=O)(O)O)COC2C(C(C(C(O2)COC)OP(=O)(O)O)OCCC(CCCCCCC)OC(=O)CCCC=CCCCCCC)NC(=O)CC(=O)CCCCCCCCCCC)O)OCCC(CCCCCCC)O
InChI: InChI=1S/C73H136N2O22P2/c1-7-12-17-22-25-28-31-36-40-45-58(77)53-63(79)74-66-70(90-51-49-57(76)44-39-34-20-15-10-4)68(82)61(94-73(66)97-99(86,87)88)56-92-72-67(75-64(80)54-59(78)46-41-37-32-29-26-23-18-13-8-2)71(69(96-98(83,84)85)62(95-72)55-89-6)91-52-50-60(47-42-35-21-16-11-5)93-65(81)48-43-38-33-30-27-24-19-14-9-3/h30,33,57,60-62,66-73,76,82H,7-29,31-32,34-56H2,1-6H3,(H,74,79)(H,75,80)(H2,83,84,85)(H2,86,87,88)/b33-30-/t57-,60-,61-,62-,66-,67-,68-,69-,70-,71-,72-,73-/m1/s1
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Terukazu Sanui, Masaaki Takeshita, Takao Fukuda, Urara Tanaka, Rehab Alshargabi, Yoshitomi Aida, Fusanori Nishimura. Roles of serum in innate immune responses of human leukocytes to synthetic lipopeptide.
International immunopharmacology.
2017 Sep; 50(?):61-68. doi:
10.1016/j.intimp.2017.06.006. [PMID: 28633072] - Clare E Bryant, A Ouellette, K Lohmann, M Vandenplas, J N Moore, D J Maskell, B A Farnfield. The cellular Toll-like receptor 4 antagonist E5531 can act as an agonist in horse whole blood.
Veterinary immunology and immunopathology.
2007 Apr; 116(3-4):182-9. doi:
10.1016/j.vetimm.2007.01.013. [PMID: 17320193] - Yasuyuki Asai. Cryoprotective effects of saccharides on the freeze-drying of sonicated vesicles of the novel lipid A analog, E5531.
Pharmaceutical development and technology.
2006; 11(2):229-33. doi:
10.1080/10837450600561430. [PMID: 16749533] - Yasuyuki Asai. Development of an injectable formulation for the novel lipid A analog E5531 using a 'pH-jump method'.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
2004 Dec; 124(12):965-72. doi:
10.1248/yakushi.124.965. [PMID: 15577266] - Anand Kumar, Eugene Bunnell, Melvyn Lynn, Ramon Anel, Kalim Habet, Alex Neumann, Joseph E Parrillo. Experimental human endotoxemia is associated with depression of load-independent contractility indices: prevention by the lipid a analogue E5531.
Chest.
2004 Sep; 126(3):860-7. doi:
10.1378/chest.126.3.860. [PMID: 15364767] - Sachiko Akashi, Shin-ichiroh Saitoh, Yasutaka Wakabayashi, Takane Kikuchi, Noriaki Takamura, Yoshinori Nagai, Yutaka Kusumoto, Koichi Fukase, Shoichi Kusumoto, Yoshiyuki Adachi, Atsushi Kosugi, Kensuke Miyake. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14.
The Journal of experimental medicine.
2003 Oct; 198(7):1035-42. doi:
10.1084/jem.20031076. [PMID: 14517279] - Y Nancy Wong, Daniel Rossignol, Jeffrey R Rose, Richard Kao, Alison Carter, Melvyn Lynn. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study.
Journal of clinical pharmacology.
2003 Jul; 43(7):735-42. doi:
10.1177/0091270003254804. [PMID: 12856387] - Susanne Becker, Matthew J Fenton, Joleen M Soukup. Involvement of microbial components and toll-like receptors 2 and 4 in cytokine responses to air pollution particles.
American journal of respiratory cell and molecular biology.
2002 Nov; 27(5):611-8. doi:
10.1165/rcmb.4868. [PMID: 12397021] - T K Means, B W Jones, A B Schromm, B A Shurtleff, J A Smith, J Keane, D T Golenbock, S N Vogel, M J Fenton. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses.
Journal of immunology (Baltimore, Md. : 1950).
2001 Mar; 166(6):4074-82. doi:
10.4049/jimmunol.166.6.4074. [PMID: 11238656] - Y Asai, S Watanabe. The effect of lipid A analog E5531 on membrane properties of dipalmitoylphosphatidylcholine.
Drug development and industrial pharmacy.
2000 Aug; 26(8):907-12. doi:
10.1081/ddc-100101317. [PMID: 10900550] - E Bunnell, M Lynn, K Habet, A Neumann, C A Perdomo, L T Friedhoff, S L Rogers, J E Parrillo. A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia.
Critical care medicine.
2000 Aug; 28(8):2713-20. doi:
10.1097/00003246-200008000-00005. [PMID: 10966240] - D M Agnese, S F Lowry. Back to the future: is lipid A an appropriate target for the therapy of sepsis?.
Critical care medicine.
2000 Aug; 28(8):3084-6. doi:
10.1097/00003246-200008000-00072. [PMID: 10966304] - J R Rose, M A Mullarkey, W J Christ, L D Hawkins, M Lynn, Y Kishi, K M Wasan, K Peteherych, D P Rossignol. Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins.
Antimicrobial agents and chemotherapy.
2000 Mar; 44(3):504-10. doi:
10.1128/aac.44.3.504-510.2000. [PMID: 10681310] - Y Asai, S Watanabe. Comparison of the effect of lipid A analog E5531 and the lipid A from Escherichia coli on phospholipid membrane properties.
Drug development and industrial pharmacy.
2000 Feb; 26(2):199-204. doi:
10.1081/ddc-100100345. [PMID: 10697757] - H Yang, J M Daun, J R Rose, W J Christ, F Gusovsky, J C Chow. Examination of chlorpromazine and other amphipathic drugs on the activity of lipopolysaccharide antagonists, E5564 and E5531.
Journal of endotoxin research.
2000; 6(6):447-52. doi:
10.1179/096805100101532405. [PMID: 11521069] - J E White, M F Tsan. Induction of TNF-alpha and MnSOD by endotoxin: effect of E5531, a synthetic non-toxic lipid A analog.
Journal of endotoxin research.
2000; 6(4):329-35. doi:
". [PMID: 11521054] - Y Asai, Y Sano, K Kikuchi, K Iwamoto, S Watanabe. The effect of divalent cations on the membrane properties and pharmacokinetics in rat of the lipid A analogue E5531.
The Journal of pharmacy and pharmacology.
2000 Jan; 52(1):39-45. doi:
10.1211/0022357001773661. [PMID: 10716601] - K M Wasan, F W Strobel, S C Parrott, M Lynn, W J Christ, L D Hawkins, D P Rossignol. Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels.
Antimicrobial agents and chemotherapy.
1999 Oct; 43(10):2562-4. doi:
10.1128/aac.43.10.2562. [PMID: 10508046] - Y Asai, S Watanabe. Effect of divalent cations on the membrane properties of the lipid A analog E5531.
Drug development and industrial pharmacy.
1999 Oct; 25(10):1107-13. doi:
10.1081/ddc-100102276. [PMID: 10529891] - Y Asai, S Watanabe. Preparation of transparent injectable formulation for lipid A analog E5531.
Drug development and industrial pharmacy.
1999 Sep; 25(9):975-82. doi:
10.1081/ddc-100102260. [PMID: 10518237] - T Kawata, J R Bristol, D P Rossignol, J R Rose, S Kobayashi, H Yokohama, A Ishibashi, W J Christ, K Katayama, I Yamatsu, Y Kishi. E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.
British journal of pharmacology.
1999 Jun; 127(4):853-62. doi:
10.1038/sj.bjp.0702596. [PMID: 10433491] - Y Asai, Y Sano, K Kikuchi, K Iwamoto, S Watanabe. Control of the dispersing process and pharmacokinetics in rats for lipid A analogue, E5531.
The Journal of pharmacy and pharmacology.
1999 May; 51(5):577-84. doi:
10.1211/0022357991772673. [PMID: 10411217] - Y Asai, Y Nozu, T Ikeuchi, R Narazaki, K Iwamoto, S Watanabe. The effect of the lipid A analog, E5531 on fever induced by endotoxin from Escherichia coli.
Biological & pharmaceutical bulletin.
1999 Apr; 22(4):432-4. doi:
10.1248/bpb.22.432. [PMID: 10328569] - S Kobayashi, T Kawata, A Kimura, K Miyamoto, K Katayama, I Yamatsu, D P Rossignol, W J Christ, Y Kishi. Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist.
Antimicrobial agents and chemotherapy.
1998 Nov; 42(11):2824-9. doi:
10.1128/aac.42.11.2824. [PMID: 9797210] - Y Asai, K Iwamoto, S Watanabe. The effect of the lipid A analog E5531 on phospholipid membrane properties.
FEBS letters.
1998 Oct; 438(1-2):15-20. doi:
10.1016/s0014-5793(98)01262-9. [PMID: 9821951] - S M Opal, R L Yu. Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.
Drugs.
1998 Apr; 55(4):497-508. doi:
10.2165/00003495-199855040-00002. [PMID: 9561340] - J Stephenson. Reflecting and regrouping after failed trials, sepsis researchers forge on.
JAMA.
1996 Mar; 275(11):823-4. doi:
". [PMID: 8596203] - W J Christ, O Asano, A L Robidoux, M Perez, Y Wang, G R Dubuc, W E Gavin, L D Hawkins, P D McGuinness, M A Mullarkey. E5531, a pure endotoxin antagonist of high potency.
Science (New York, N.Y.).
1995 Apr; 268(5207):80-3. doi:
10.1126/science.7701344. [PMID: 7701344] - T Kawata, J R Bristol, J R Rose, D P Rossignol, W J Christ, O Asano, G R Dubuc, W E Gavin, L D Hawkins, Y Kishi. Anti-endotoxin activity of a novel synthetic lipid A analog.
Progress in clinical and biological research.
1995; 392(?):499-509. doi:
". [PMID: 8524958]